4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 111 | 147 | +36 |
| Shares | 42.4M | 56.4M | +13.9M (+32.8%) |
| Value | $859.8M | $1.79B | +$934.7M (+108.7%) |
New holders (54)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (18)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Point72 Asset Management, L.P. | 416,020 | $8.43M |
| Sectoral Asset Management Inc | 142,510 | $2.89M |
| Vontobel Holding Ltd. | 142,510 | $2.89M |
| Acuta Capital Partners, LLC | 74,500 | $1.51M |
| Laurion Capital Management LP | 52,828 | $1.07M |
| HSBC Holdings PLC | 18,654 | $383.9K |
| Royce & Associates LP | 18,769 | $380.3K |
| Bridgeway Capital Management, LLC | 17,400 | $352.5K |
| State Board of Administration of Florida Retirement System | 11,187 | $226.6K |
| HRT Financial LP | 9,991 | $202.0K |
| Sandia Investment Management LP | 4,486 | $90.9K |
| Group One Trading, L.P. | 3,691 | $74.8K |
| Itau Unibanco Holding S.A. | 1,646 | $33.3K |
| Advisor Group Holdings, Inc. | 1,575 | $31.9K |
| Cutler Group LP | 1,000 | $20.0K |
| Harbour Investments, Inc. | 25 | $507 |
| McGlone Suttner Wealth Management, Inc. | 25 | $507 |
| Able Wealth Management LLC | 9 | $182 |